Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy

Jyothi U. Menon, Aneetta Kuriakose, Roshni Iyer, Elizabeth Hernandez, Leah Gandee, Shanrong Zhang, Masaya Takahashi, Zhang Zhang, Debabrata Saha, Kytai T. Nguyen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cells. In this research, we have developed a folate receptor-targeting multifunctional dual drug-loaded nanoparticle (MDNP) containing a poly(N-isopropylacrylamide)-carboxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-radiotherapy to effectively treat lung cancers. The formulation provided controlled releases of the encapsulated therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy. The MDNPs showed biphasic NU7441 release and pH-dependent release of gemcitabine. These nanoparticles also demonstrated good stability, excellent hemocompatibility, outstanding in vitro cytocompatibility with alveolar Type I cells, and dose-dependent caveolae-mediated in vitro uptake by lung cancer cells. In addition, they could be encapsulated with superparamagnetic iron oxide (SPIO) nanoparticles and visualized by MRI in vivo. Preliminary in vivo results demonstrated the low toxicity of these particles and their use in chemo-radiotherapy to effectively reduce lung tumors. These results indicate that MDNPs can potentially be used as nano-vehicles to provide simultaneous chemotherapy and radiation sensitization for lung cancer treatment.

Original languageEnglish (US)
Article number13249
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Nanoparticles
Lung Neoplasms
gemcitabine
Pharmaceutical Preparations
Radiotherapy
Therapeutics
Caveolae
Delayed Diagnosis
Radio
Folic Acid
Radiation
Drug Therapy
Lung
Research
Neoplasms
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
In Vitro Techniques

ASJC Scopus subject areas

  • General

Cite this

Menon, J. U., Kuriakose, A., Iyer, R., Hernandez, E., Gandee, L., Zhang, S., ... Nguyen, K. T. (2017). Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. Scientific Reports, 7(1), [13249]. https://doi.org/10.1038/s41598-017-13320-4

Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. / Menon, Jyothi U.; Kuriakose, Aneetta; Iyer, Roshni; Hernandez, Elizabeth; Gandee, Leah; Zhang, Shanrong; Takahashi, Masaya; Zhang, Zhang; Saha, Debabrata; Nguyen, Kytai T.

In: Scientific Reports, Vol. 7, No. 1, 13249, 01.12.2017.

Research output: Contribution to journalArticle

Menon, JU, Kuriakose, A, Iyer, R, Hernandez, E, Gandee, L, Zhang, S, Takahashi, M, Zhang, Z, Saha, D & Nguyen, KT 2017, 'Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy', Scientific Reports, vol. 7, no. 1, 13249. https://doi.org/10.1038/s41598-017-13320-4
Menon JU, Kuriakose A, Iyer R, Hernandez E, Gandee L, Zhang S et al. Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. Scientific Reports. 2017 Dec 1;7(1). 13249. https://doi.org/10.1038/s41598-017-13320-4
Menon, Jyothi U. ; Kuriakose, Aneetta ; Iyer, Roshni ; Hernandez, Elizabeth ; Gandee, Leah ; Zhang, Shanrong ; Takahashi, Masaya ; Zhang, Zhang ; Saha, Debabrata ; Nguyen, Kytai T. / Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{a99b4b3305c44e578680f1ea4100887d,
title = "Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy",
abstract = "Late-stage diagnosis of lung cancer occurs ~95{\%} of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cells. In this research, we have developed a folate receptor-targeting multifunctional dual drug-loaded nanoparticle (MDNP) containing a poly(N-isopropylacrylamide)-carboxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-radiotherapy to effectively treat lung cancers. The formulation provided controlled releases of the encapsulated therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy. The MDNPs showed biphasic NU7441 release and pH-dependent release of gemcitabine. These nanoparticles also demonstrated good stability, excellent hemocompatibility, outstanding in vitro cytocompatibility with alveolar Type I cells, and dose-dependent caveolae-mediated in vitro uptake by lung cancer cells. In addition, they could be encapsulated with superparamagnetic iron oxide (SPIO) nanoparticles and visualized by MRI in vivo. Preliminary in vivo results demonstrated the low toxicity of these particles and their use in chemo-radiotherapy to effectively reduce lung tumors. These results indicate that MDNPs can potentially be used as nano-vehicles to provide simultaneous chemotherapy and radiation sensitization for lung cancer treatment.",
author = "Menon, {Jyothi U.} and Aneetta Kuriakose and Roshni Iyer and Elizabeth Hernandez and Leah Gandee and Shanrong Zhang and Masaya Takahashi and Zhang Zhang and Debabrata Saha and Nguyen, {Kytai T.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-13320-4",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy

AU - Menon, Jyothi U.

AU - Kuriakose, Aneetta

AU - Iyer, Roshni

AU - Hernandez, Elizabeth

AU - Gandee, Leah

AU - Zhang, Shanrong

AU - Takahashi, Masaya

AU - Zhang, Zhang

AU - Saha, Debabrata

AU - Nguyen, Kytai T.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cells. In this research, we have developed a folate receptor-targeting multifunctional dual drug-loaded nanoparticle (MDNP) containing a poly(N-isopropylacrylamide)-carboxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-radiotherapy to effectively treat lung cancers. The formulation provided controlled releases of the encapsulated therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy. The MDNPs showed biphasic NU7441 release and pH-dependent release of gemcitabine. These nanoparticles also demonstrated good stability, excellent hemocompatibility, outstanding in vitro cytocompatibility with alveolar Type I cells, and dose-dependent caveolae-mediated in vitro uptake by lung cancer cells. In addition, they could be encapsulated with superparamagnetic iron oxide (SPIO) nanoparticles and visualized by MRI in vivo. Preliminary in vivo results demonstrated the low toxicity of these particles and their use in chemo-radiotherapy to effectively reduce lung tumors. These results indicate that MDNPs can potentially be used as nano-vehicles to provide simultaneous chemotherapy and radiation sensitization for lung cancer treatment.

AB - Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cells. In this research, we have developed a folate receptor-targeting multifunctional dual drug-loaded nanoparticle (MDNP) containing a poly(N-isopropylacrylamide)-carboxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-radiotherapy to effectively treat lung cancers. The formulation provided controlled releases of the encapsulated therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy. The MDNPs showed biphasic NU7441 release and pH-dependent release of gemcitabine. These nanoparticles also demonstrated good stability, excellent hemocompatibility, outstanding in vitro cytocompatibility with alveolar Type I cells, and dose-dependent caveolae-mediated in vitro uptake by lung cancer cells. In addition, they could be encapsulated with superparamagnetic iron oxide (SPIO) nanoparticles and visualized by MRI in vivo. Preliminary in vivo results demonstrated the low toxicity of these particles and their use in chemo-radiotherapy to effectively reduce lung tumors. These results indicate that MDNPs can potentially be used as nano-vehicles to provide simultaneous chemotherapy and radiation sensitization for lung cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85031739787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031739787&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-13320-4

DO - 10.1038/s41598-017-13320-4

M3 - Article

C2 - 29038584

AN - SCOPUS:85031739787

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 13249

ER -